These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 29120264)

  • 21. Valbenazine for the treatment of tardive dyskinesia.
    Müller T
    Expert Rev Neurother; 2017 Dec; 17(12):1135-1144. PubMed ID: 28971695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
    Khorassani F; Luther K; Talreja O
    Am J Health Syst Pharm; 2020 Jan; 77(3):167-174. PubMed ID: 31974564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia.
    Davis MC; Miller BJ; Kalsi JK; Birkner T; Mathis MV
    N Engl J Med; 2017 Jun; 376(26):2503-2506. PubMed ID: 28489481
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
    Caroff SN; Aggarwal S; Yonan C
    J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical development of valbenazine for tics associated with Tourette syndrome.
    Farber RH; Angelov A; Kim K; Carmack T; Thai-Cuarto D; Roberts E
    Expert Rev Neurother; 2021 Apr; 21(4):393-404. PubMed ID: 33682568
    [No Abstract]   [Full Text] [Related]  

  • 26. Valbenazine in the treatment of tardive dyskinesia.
    Witek N; Comella C
    Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia.
    Kim AP; Baker DE; Levien TL
    Consult Pharm; 2018 Apr; 33(4):201-209. PubMed ID: 29609698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):65-68. PubMed ID: 29667946
    [No Abstract]   [Full Text] [Related]  

  • 29. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia.
    Dorfman BJ; Jimenez-Shahed J
    Expert Rev Neurother; 2021 Jan; 21(1):9-20. PubMed ID: 33174440
    [No Abstract]   [Full Text] [Related]  

  • 30. VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine).
    Harriott ND; Williams JP; Smith EB; Bozigian HP; Grigoriadis DE
    Prog Med Chem; 2018; 57(1):87-111. PubMed ID: 29680151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Valbenazine (Ingrezza) for tardive dyskinesia.
    Med Lett Drugs Ther; 2017 May; 59(1521):83-84. PubMed ID: 28520698
    [No Abstract]   [Full Text] [Related]  

  • 32. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
    Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tetrabenazine: for chorea associated with Huntington's disease.
    Scott LJ
    CNS Drugs; 2011 Dec; 25(12):1073-85. PubMed ID: 22133328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valbenazine granted breakthrough drug status for treating tardive dyskinesia.
    Müller T
    Expert Opin Investig Drugs; 2015 Jun; 24(6):737-42. PubMed ID: 25809133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.
    Gibson JS; Claassen DO
    Expert Opin Pharmacother; 2021 Jun; 22(8):1015-1024. PubMed ID: 33550875
    [No Abstract]   [Full Text] [Related]  

  • 36. Deutetrabenazine in the treatment of tardive dyskinesia.
    Niemann N; Jimenez-Shahed J
    Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deuterium Tetrabenazine for Tardive Dyskinesia.
    Cummings MA; Proctor GJ; Stahl SM
    Clin Schizophr Relat Psychoses; 2018 Jan; 11(4):214-220. PubMed ID: 29341821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medication Options and Clinical Strategies for Treating Tardive Dyskinesia.
    Citrome LL
    J Clin Psychiatry; 2020 Jan; 81(2):. PubMed ID: 31995679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Valbenazine: First Global Approval.
    Kim ES
    Drugs; 2017 Jul; 77(10):1123-1129. PubMed ID: 28578484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tardive Dyskinesia: New Treatments Available.
    Limandri BJ
    J Psychosoc Nurs Ment Health Serv; 2019 May; 57(5):11-14. PubMed ID: 31042295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.